Latest news with #biologics
Globe and Mail
13 hours ago
- Business
- Globe and Mail
Blood Cell Factors Market Expected to Touch USD 4.31 Bn by 2032, CAGR of 3.6% Detailed in New Report
The global blood cell factors market growth is driven by the increasing prevalence of blood disorders, advancements in healthcare infrastructure, and rising demand for effective treatments. Additionally, growing awareness about blood cell factors and their role in treating various blood-related conditions are expected to fuel the market growth. Blood Cell Factors Market Insights The Blood Cell Factors industry is experiencing robust expansion driven by rising hemophilia treatment demand and novel biologics pipelines. This expert analysis explores market size, dynamics, and actionable insights to guide strategic decision-making in 2025–2032. The Global Blood Cell Factors Market size is estimated to be valued at USD 3.37 Bn in 2025 and is expected to reach USD 4.31 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 3.6% from 2025 to 2032. According to the latest Blood Cell Factors market size assessment and Blood Cell Factors market report, global market revenue surpassed USD 3.4 Bn in 2024, indicating an upward shift in market share across major regions. This market forecast underscores expanding industry size and business growth opportunities. Market Key Takeaways: Region: • North America: Strong R&D investments in recombinant factors drive advanced product launches. • Latin America: Rising healthcare infrastructure improvements accelerate treatment adoption. • Europe: Regulatory harmonization fosters cross-border supply chains. • Asia Pacific: Expanding manufacturing capacity and favorable pricing boost volume. • Middle East: Government-backed hemophilia programs underpin demand growth. • Africa: Emerging import channels and NGO support enhance access. Segment Covers: • Product Type: – Recombinant Factors: Example: Amgen's 2024 launch of Factor VIII rAHFV captured 42% of new biologics uptake. – Plasma-Derived Factors: Sanofi's Purified FVIII retains stable pricing leadership in 2025. – Gene Therapy Platforms: Early-stage pipelines by Regeneron target one-dose cures. • Application: – Hemophilia A/B: Eli Lilly's factor IX pegylated formulation grew 28% in 2024 revenues. – Von Willebrand Disease: Pfizer's new multi‐domain VWF therapy gained EMA approval in 2024. • End User: – Hospitals & Clinics: Accounted for 65% of procurement in 2024. – Specialty Centers: Focused infusion protocols drive repeat purchase patterns. Growth Factors: • Rising Prevalence of Coagulation Disorders: The global hemophilia population increased by 4.5% between 2023 and 2024, driving factor consumption. • Strategic Partnerships: In 2024, Roche's collaboration with a biotech startup increased manufacturing capacity by 15% and expanded contract manufacturing revenue by USD 80 Mn. • Blood Cell Factors market share gains hinge on targeted rebates and patient support programs in North America and Europe, lifting volume growth despite pricing pressures. • Increased public funding for rare diseases in Japan and Australia boosted factor adoption by 12% in 2024. Book the Latest Edition of this Market Study Get Up to 25 % Discount: Market Trends: • Personalized Medicine: Tailored dosing algorithms using AI-driven pharmacokinetic models reduced bleed rates by 30% in 2024 trials. • Biosimilar Entrants: Novartis's pipeline biosimilar of FVIII (expected 2025 launch) is projected to undercut reference pricing by 20%. • Digital Adherence Tools: Mobile infusion tracking apps improved on-time dosing by 18% across 2024 real-world studies. • Blood Cell Factors market trends indicate heightened M&A activity—with Teva's acquisition of a plasma facility in 2024 enhancing Asia Pacific supply by 25%. Actionable Insights: • Production Capacity: Global recombinant factor capacity rose to 150 kg in 2024, up 10% YOY, enabling wider supply. • Pricing Benchmarks: Median USD 0.85/IU for FVIII in Western Europe vs. USD 0.65/IU in Asia Pacific illustrates import-driven discounts. • Exports & Imports: Asia Pacific exported USD 220 Mn of plasma-derived factors in 2024, while Africa imported USD 90 Mn, reflecting demand-supply gaps. • Use-Case Volumes: Hospital procurement volumes for prophylactic regimens grew 14% in Latin America in 2024, outpacing on-demand therapy. • Nano-Indicators: Patient registry expansions in the Middle East added 5,000 new documented cases in 2024, informing localized forecasting models. • Blood Cell Factors market revenue analyses highlight cost-per-patient as a leading macro-indicator for future investment. Key Players: • Amgen Inc. • Johnson & Johnson • Roche Holding AG • Novartis AG • Pfizer Inc. • Bristol-Myers Squibb Company • Eli Lilly Company • Gilead Sciences Inc. • Sanofi S.A. • Merck & Co. Inc. • Teva Pharmaceutical Industries Ltd. • AbbVie Inc. • Celgene Corporation • Takeda Pharmaceutical Company Limited • Regeneron Pharmaceuticals Inc. Get Customization on this Report: Competitive Strategies: – Roche's 2024 capacity partnership with Biogen boosted contract revenues by USD 80 Mn and reduced production costs by 12%. – Novartis's biosimilar rollout strategy undercut reference FVIII pricing by 20%, capturing 8% market share in Europe within six months. – Pfizer's bundled care agreements with specialty clinics in North America in 2024 increased annualized purchases by 22%. Frequently Asked Questions 1. Who are the dominant players in the Blood Cell Factors market? Major players include Amgen, Roche, Novartis, Pfizer, and Sanofi, each commanding significant market share through diversified portfolios and strategic alliances. 2. What will be the size of the Blood Cell Factors market in the coming years? The market is forecast to grow from USD 3.37 Bn in 2025 to USD 4.31 Bn by 2032 at a 3.6% CAGR. 3. Which end-user industry has the largest growth opportunity? Hospitals & clinics represent the largest segment, accounting for over 65% of revenues in 2024, driven by prophylactic treatment mandates. 4. How will market development trends evolve over the next five years? Trends include AI-enabled dosing, gene therapy maturation, and biosimilar price competition, reshaping market dynamics and business growth strategies. 5. What is the nature of the competitive landscape and challenges in the Blood Cell Factors market? Intense R&D races, biosimilar threats, and supply-chain complexities define the competitive landscape, while high manufacturing costs remain a key restraint. 6. What go-to-market strategies are commonly adopted in the Blood Cell Factors market? Strategies include co-development partnerships, patient support services, value-based contracts, and digital adherence platforms to drive uptake and retention. About Coherent Market Insights Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Yahoo
20 hours ago
- Business
- Yahoo
ADMA Biologics (ADMA) Drops for 5th Consecutive Day – Here's Why
We recently published a list of 10 Stocks Take A Shocking Nosedive. ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the worst-performing stocks on Thursday. ADMA Biologics saw its share prices decline by 4.02 percent on Wednesday to finish at $18.13 apiece, as investors parked funds amid the lack of fresh catalysts to spark buying. Wednesday's drop marked the company's fifth straight session in the red territory, trading lower in line with its president and CEO's disposition of shares in the company. According to a regulatory filing, ADMA Biologics, Inc. (NASDAQ:ADMA) President and CEO Adam Grossman sold 21,000 ADMA shares at a price of $20.81 apiece on June 16 for a total value of $437,010. On the same day, he acquired 15,000 shares at a price of $5.4 apiece for a total of $81,000. An independent distributor in their pharmacy with a range of biopharmaceutical products on display. ADMA Biologics, Inc. (NASDAQ:ADMA) said that the transaction was in line with the Rule 10b5-1 trading plan entered into between Grossman and Fidelity Brokerage Services LLC. While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Globe and Mail
a day ago
- Business
- Globe and Mail
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer's revenues in 2024 and in the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline. Pfizer's oncology revenues grew 7% on an operational basis in the first quarter of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Pfizer has also ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer has also advanced its oncology clinical pipeline with several candidates entering late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin. In May, Pfizer inked an exclusive licensing deal with China's 3SBio for the latter's dual PD-1 and VEGF inhibitor, which will strengthen its oncology pipeline. Pfizer is also working on expanding the labels of approved oncology products like Padcev and Adcetris, among others. With all the above developments, Pfizer's future in cancer treatment looks promising. Competition in the Oncology Space Other large players in the oncology space are AstraZeneca AZN, Merck MRK and Bristol-Myers BMY. For AstraZeneca, oncology sales now comprise around 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Merck's key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Bristol-Myers' key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues. PFE's Price Performance, Valuation and Estimates Pfizer's stock has declined 6.8% so far this year against an increase of 0.2% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 7.77 forward earnings, lower than 15.05 for the industry and the stock's 5-year mean of 10.90. The Zacks Consensus Estimate for 2025 earnings has risen from $2.98 per share to $3.06 per share, while that for 2026 has gone up from $3.00 to $3.09 per share over the past 60 days. Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
Medscape
a day ago
- Health
- Medscape
Can Dose Spacing of IL-17i Maintain Efficacy in Psoriasis?
Dose spacing of interleukin-17 (IL-17) inhibitors maintained therapeutic efficacy in patients with stable psoriasis, with no substantial differences observed between secukinumab and brodalumab and acceptable survival of the dose-spacing regimen for up to 12 months. METHODOLOGY: This retrospective cohort study analysed the effectiveness and survival of patients with psoriasis undergoing therapeutic biologic dose spacing of secukinumab or brodalumab. The analysis included 80 patients; 38.75% of them received secukinumab and 61.25% received brodalumab. Dose spacing was defined as extending secukinumab dosing to every 6 weeks and brodalumab to every 3 weeks after induction. All patients underwent 50% dose spacing of the approved range after a mean treatment duration of 35 months. Researchers monitored mean Psoriasis Area Severity Index (PASI) scores, PASI100, PASI90, and PASI ≤ 1. The mean follow-up duration under the dose-spacing regimen was 6.7 months. TAKEAWAY: The mean PASI value was 0.7 after 3 months of dose spacing and 0.1 after 12 months. No significant differences in mean PASI scores were observed between secukinumab and brodalumab at any timepoint after dose spacing. PASI100 achievement was 91.25% at dose-spacing initiation and remained stable throughout the following year; 99% of patients achieved PASI90 and 100% achieved PASI ≤ 1 at dose-spacing initiation, and both rates were maintained at 12 months. The 12-month drug survival rate for the dose-spacing regimen was 66.1%, with 25% of patients returning to standard dosage and 66.7% of these cases regaining PASI100. Secukinumab demonstrated higher drug survival after dose spacing than brodalumab (78.3% vs 58.9%). IN PRACTICE: "No significant differences in effectiveness were found between secukinumab and brodalumab in patients undergoing a D-S [dose-spacing] regimen. Overall, dose de-escalation of IL-17 inhibitors in patients with psoriasis who have achieved a stable response seems an effective therapeutic strategy, even if 2 of 5 patients returned to the original regimen after 1 year. When coming back to the standard regimen after D-S, PASI was regained by two-thirds of patients after 6 months," the authors of the study wrote. SOURCE: This study was led by Luca Mastorino, Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy. It was published online on June 12, 2025, in Clinical and Experimental Dermatology . LIMITATIONS: The study's real-life design and retrospective nature may have introduced potential biases. The relatively small sample size could have affected the generalisability of the findings. The analysis of observed cases may have affected the interpretation of long-term outcomes. DISCLOSURES: This study did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors reported having no relevant conflicts of interest.
Yahoo
3 days ago
- Business
- Yahoo
Eli Lilly, Juvena Therapeutics Partner to Develop Muscle-Boosting Drugs Using AI Platform
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a partnership with Juvena Therapeutics to develop new muscle-boosting drugs. The collaboration is valued at over $650 million, with the majority of this sum tied to the achievement of specific development and commercialization milestones. The core of the partnership involves Eli Lilly using Juvena's AI-enabled screening platform, which is known as JuvNET. This platform specializes in mapping the therapeutic potential of proteins secreted by stem cells. By combining a vast database of secreted proteins with disease phenotypes, in silico and in vitro human cell screening, and other advanced capabilities, JuvNET is designed to identify promising drug candidates that can improve muscle health and body composition. Eli Lilly's interest in muscle-boosting drugs has surged in parallel with the popularity of GLP-1 weight-loss medication. These medications are effective for weight loss but can also lead to a reduction in lean muscle mass, which can impair physical function and increase the risk of falls and fractures, especially in older individuals and senior citizens. Eli Lilly aims to address this concern. Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals internationally. Juvena Therapeutics is a clinical-stage biotechnology company on a mission to research, develop, and commercialize tissue restorative biologics. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
